ARTICLE | Company News
BMS, Biogen deal
April 14, 2017 4:33 PM UTC
Bristol-Myers granted Biogen exclusive rights to BMS-986168. The mAb targeting microtubule-associated protein tau (tau; MAPT; FTDP-17) has completed a Phase Ib trial to treat progressive supranuclear palsy (PSP). Biogen said it intends to start Phase II trials “rapidly” in PSP and Alzheimer's disease. ...
BCIQ Target Profiles